Adv. TNBC BRCA1/2+ Responds Better to Carboplatin v. Taxotere

Options
Moderators
Moderators Member Posts: 25,912
edited June 2018 in Genetic Testing

Advanced-Stage, Triple-Negative Breast Cancer in Women With BRCA1/2 Mutation Seems to Respond Better to Carboplatin Than Taxotere
June 26, 2018

Women diagnosed with advanced-stage, triple-negative breast cancer who have a BRCA1 or BRCA2 mutation have a better response to carboplatin than Taxotere. Read more...

Categories